NCT06818097View on ClinicalTrials.gov

Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC

CompletedOBSERVATIONAL
Enrollment

68

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2025

Conditions
Advanced HCCSystemic TherapyChemotherapyImmunotherapyTargeted TherapyEfficacy and Safety
Interventions
DRUG

TKI

Lenvatinib

DRUG

anti PD-1

Sintilimab or Camrelizumab or Tislelizumab

DRUG

XELOX chemotherapy

Capecitabine and Oxaliplatin

Trial Locations (1)

510120

Sen Memorial Hospital, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

NCT06818097 - Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC | Biotech Hunter | Biotech Hunter